
Servier Strengthens Its Portfolio with Edgewise Therapeutics Acquisition
In a strategic move, Servier is set to acquire Edgewise Therapeutics' muscular dystrophy division, expanding its innovative drug portfolio. This acquisition signals Servier's commitment to enhancing treatment options in the muscular dystrophy arena. Read on to explore the implications and details of this significant business decision.
Read full article




























